OSLO, Norway, Oct. 9, 2019 /PRNewswire/ -- Targovax ASA
(OSE: TRVX), announces that clinical data on the company's lead
product candidate ONCOS-102, a genetically modified oncolytic
adenovirus which has been engineered to selectively infect and
replicate in cancer cells, will be presented at the Society for
Immunotherapy of Cancer (SITC) Annual Meeting being held
November 6-10, 2019, in Maryland, USA.
Title:
|
A pilot study of
engineered adenovirus ONCOS-102 in combination with pembrolizumab
in checkpoint inhibitor refractory advanced or unresectable
melanoma
|
Authors:
|
Alexander N.
Shoushtari, MD; Anthony J. Olszanski, MD, RPh; Thomas J. Hornyak,
MD; Jedd D. Wolchok, MD, PhD; Sylvia Vetrhus; Karianne Risberg
Handeland; Lukasz Kuryk, PhD; Magnus Jaderberg, MD;
|
Date:
|
9 November
2019
|
Time:
|
5:30 pm - 5:45
pm
|
Presenter:
|
Dr. Alexander
Shoushtari, Principal Investigator, MSKCC, NYC
|
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-selected-for-oral-presentation-at-society-for-immunotherapy-of-cancer--sitc--2019-annual-me,c2928505
View original
content:http://www.prnewswire.com/news-releases/targovax-selected-for-oral-presentation-at-society-for-immunotherapy-of-cancer-sitc-2019-annual-meeting-300934520.html
SOURCE Targovax